1. Phylogeny  
   JAK1 is a member of the Janus kinase family, a conserved group of non‐receptor tyrosine kinases that are found in all vertebrates and have orthologs across many metazoan species (babon2014themolecularregulation pages 14-15). Within the human kinome, JAK1 is grouped with JAK2, JAK3, and TYK2 and shares the common domain architecture of an N‐terminal FERM domain, an SH2-like domain, a central pseudokinase (JH2) domain and a C‐terminal kinase (JH1) domain (kwon2022moleculardissectionof pages 1-2, li2017insightsontype pages 14-20). Evolutionarily, JAK1 and its family members are thought to have arisen from a common ancestral kinase and are part of a core set of signaling proteins essential for cytokine responses—a lineage that can be traced back to the last common ancestor of eukaryotes (babon2014themolecularregulation pages 14-15, raivolaUnknownyearmolecularregulationof pages 23-27).
2. Reaction Catalyzed  
   JAK1 catalyzes the phosphorylation reaction that transfers a phosphate group from ATP to tyrosine residues on substrate proteins. The chemical reaction can be represented as:  
     ATP + [protein]–Tyr → ADP + [protein]–Tyr‐phosphate + H⁺  
   In cytokine receptor signaling, JAK1 phosphorylates specific tyrosine residues on receptor intracellular domains as well as on STAT transcription factors, thereby initiating downstream signal transduction (babon2014themolecularregulation pages 1-3, babon2014themolecularregulation pages 11-13).
3. Cofactor Requirements  
   The kinase activity of JAK1 is strictly dependent on ATP as a phosphate donor, and divalent metal ions, typically Mg²⁺, are required as cofactors to coordinate ATP binding and facilitate effective phosphotransfer (babon2014themolecularregulation pages 4-6, castelosoccio2023proteinkinasesdrug pages 5-7).
4. Substrate Specificity  
   JAK1, as a tyrosine kinase, exhibits a substrate specificity that is defined by its intrinsic catalytic properties. It phosphorylates tyrosine residues on specific substrates, which include the intracellular domains of cytokine receptors and STAT (signal transducers and activators of transcription) proteins. Recent studies on the intrinsic substrate specificities of the human tyrosine kinome show that while a consensus motif may not be as sharply defined as that for serine/threonine kinases, tyrosine kinases demonstrate a preference for certain surrounding amino acid contexts that facilitate recognition and efficient phosphorylation (Yaron-Barir2024, Johnson2023 provide complementary data for kinase families but for JAK1 the intrinsic substrate specificity is mostly derived from its role in phosphorylating receptor-associated tyrosine sites that later serve as docking platforms for STAT proteins) (babon2014themolecularregulation pages 9-11, castelosoccio2023proteinkinasesdrug pages 7-8).
5. Structure  
   JAK1 exhibits a modular domain organization characteristic of Janus kinases. Starting at the N-terminus, it contains a FERM (four-point-one, ezrin, radixin, moesin) domain that mediates interactions with cytokine receptor motifs and plays a role in proper subcellular targeting (babon2014themolecularregulation pages 1-3, raivolaUnknownyearmolecularregulationof pages 27-29). Following the FERM domain is an SH2-like domain which, although it does not function in classical phosphotyrosine recognition, contributes structurally to receptor binding by stabilizing the association with receptor intracellular segments (babon2014themolecularregulation pages 6-7). Centrally located is the pseudokinase domain (JH2), an evolutionarily conserved module that, despite lacking full catalytic competence due to missing key catalytic residues, plays a critical regulatory role by maintaining the kinase domain (JH1) in an autoinhibited state in the absence of cytokine stimulation (babon2014themolecularregulation pages 4-6, li2017insightsontype pages 26-30). The C-terminal JH1 domain is the catalytically active tyrosine kinase region and displays a bilobed structure typical of protein kinases with an N-terminal lobe containing a glycine-rich loop (P-loop) for phosphate binding and a C-terminal lobe that includes critical features such as the activation loop (A-loop) and the conserved catalytic lysine residue required for ATP binding (kwon2022moleculardissectionof pages 4-6, babon2014themolecularregulation pages 7-9). Additional structural elements such as the hydrophobic spine and the C-helix within the kinase domain are crucial for catalytic regulation and conformational changes upon activation (niranjan2014functionalcharacterizationof pages 38-41, raivolaUnknownyearmolecularregulationof pages 44-48). Together, these domains coordinate receptor binding, autoinhibition, and activation through conformational rearrangements induced by cytokine receptor dimerization (babon2014themolecularregulation pages 26-28, raivolaUnknownyearmolecularregulationof pages 30-33).
6. Regulation  
   JAK1 activity is regulated by multiple mechanisms that include both intrinsic autoinhibition and extrinsic modulation by interacting proteins. The pseudokinase domain (JH2) plays a central role by maintaining the kinase (JH1) in an autoinhibited conformation under basal conditions; receptor-mediated conformational changes relieve this autoinhibition to allow trans-phosphorylation and activation of the kinase domains (babon2014themolecularregulation pages 4-6, raivolaUnknownyearmolecularregulationof pages 143-152). Activation of JAK1 involves phosphorylation at critical tyrosine residues in the activation loop (di-tyrosine motif), which is essential for its catalytic activity and subsequent STAT phosphorylation (babon2014themolecularregulation pages 11-13, raivolaUnknownyearmolecularregulationof pages 161-163). In addition, negative regulatory proteins such as members of the suppressors of cytokine signaling (SOCS) family bind to the receptor-JAK complex and inhibit JAK1 kinase activity, while protein tyrosine phosphatases (for instance, SHP1 and SHP2) dephosphorylate activated JAK1, thereby attenuating downstream signaling (braidotti2023terapiadiprecisione pages 81-83, raivolaUnknownyearmolecularregulationof pages 37-40). Mutations within the pseudokinase domain, such as those analogous to the V617F mutation in JAK2 (V658F in JAK1), disrupt the autoinhibitory interactions and result in constitutive activation, which has been associated with several hematological malignancies (babon2014themolecularregulation pages 4-6, raivolaUnknownyearmolecularregulationof pages 152-154).
7. Function  
   JAK1 is a critical mediator of cytokine receptor signaling pathways and is ubiquitously expressed in human tissues. It plays an essential role in transducing signals from a variety of cytokines, including type I and type II interferons (IFN-α, IFN-β, and IFN-γ), interleukin-2 (IL-2) receptors, and interleukin-10 (IL-10) receptors (babon2014themolecularregulation pages 1-3, babon2014themolecularregulation pages 11-13). Upon cytokine binding to their cognate receptors, JAK1 becomes activated through receptor dimerization, leading to trans-phosphorylation events that create docking sites for STAT proteins. Phosphorylated STATs subsequently form homodimers or heterodimers, translocate to the nucleus, and regulate gene transcription involved in immune response, cell growth, differentiation, and apoptosis (castelosoccio2023proteinkinasesdrug pages 5-7, braidotti2023terapiadiprecisione pages 13-15). Furthermore, JAK1 can act as a kinase partner to modulate signaling by transactivating other JAK family members associated with receptor complexes, thereby enhancing the fidelity and strength of the cytokine response (babon2014themolecularregulation pages 1-3, malemud2018theroleof pages 1-2). In addition, constitutive or aberrant activation of JAK1, as observed in gain-of-function somatic mutations, is implicated in the pathogenesis of hematological malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and other immune-mediated disorders (raivolaUnknownyearmolecularregulationof pages 154-156, raivolaUnknownyearmolecularregulationof pages 161-163).
8. Other Comments  
   Multiple small-molecule inhibitors have been developed to target the ATP-binding site of JAK1, either alone or in combination with other JAK family members. Examples of these clinical compounds include ruxolitinib, tofacitinib, baricitinib, and more recent selective inhibitors such as filgotinib and abrocitinib (castelosoccio2023proteinkinasesdrug pages 7-8, zarrin2021kinaseinhibitionin pages 5-6). Inhibitor development faces challenges due to the high conservation of the ATP-binding pocket across kinases; therefore, alternative approaches targeting regulatory domains, such as the pseudokinase domain, are being explored for improved specificity (raivolaUnknownyearmolecularregulationof pages 154-156, kwon2022moleculardissectionof pages 6-8). Disease associations of JAK1 extend beyond hematological malignancies to include autoimmune and inflammatory disorders, as well as immune deficiencies resulting from loss-of-function mutations. Furthermore, JAK1’s role in interferon receptor signaling implicates it in antiviral immunity and immune surveillance (babon2014themolecularregulation pages 3-4, braidotti2023terapiadiprecisione pages 81-83).
9. References
10. babon2014themolecularregulation pages 1-3
11. babon2014themolecularregulation pages 11-13
12. babon2014themolecularregulation pages 14-15
13. babon2014themolecularregulation pages 26-28
14. babon2014themolecularregulation pages 4-6
15. babon2014themolecularregulation pages 6-7
16. babon2014themolecularregulation pages 7-9
17. braidotti2023terapiadiprecisione pages 13-15
18. braidotti2023terapiadiprecisione pages 6-9
19. braidotti2023terapiadiprecisione pages 81-83
20. castelosoccio2023proteinkinasesdrug pages 5-7
21. castelosoccio2023proteinkinasesdrug pages 7-8
22. foulkes2018biochemicalanalysisof pages 59-63
23. kwon2022moleculardissectionof pages 1-2
24. kwon2022moleculardissectionof pages 2-4
25. kwon2022moleculardissectionof pages 4-6
26. kwon2022moleculardissectionof pages 6-8
27. li2017insightsontype pages 14-20
28. li2017insightsontype pages 20-22
29. malemud2018theroleof pages 1-2
30. raivolaUnknownyearmolecularregulationof pages 105-107
31. raivolaUnknownyearmolecularregulationof pages 11-14
32. raivolaUnknownyearmolecularregulationof pages 14-19
33. raivolaUnknownyearmolecularregulationof pages 143-152
34. raivolaUnknownyearmolecularregulationof pages 152-154
35. raivolaUnknownyearmolecularregulationof pages 154-156
36. raivolaUnknownyearmolecularregulationof pages 161-163
37. raivolaUnknownyearmolecularregulationof pages 37-40
38. raivolaUnknownyearmolecularregulationof pages 44-48
39. raivolaUnknownyearmolecularregulationof pages 48-50
40. raivolaUnknownyearmolecularregulationof pages 87-90
41. zarrin2021kinaseinhibitionin pages 5-6
42. klebl…2011proteinkinasesas pages 143-145
43. li2017insightsontype pages 156-158
44. li2017insightsontype pages 22-26
45. li2017insightsontype pages 26-30
46. niranjan2014functionalcharacterizationof pages 10-14
47. niranjan2014functionalcharacterizationof pages 110-111
48. niranjan2014functionalcharacterizationof pages 14-19
49. niranjan2014functionalcharacterizationof pages 38-41
50. niranjan2014functionalcharacterizationof pages 41-46
51. niranjan2014functionalcharacterizationof pages 96-99
52. raivolaUnknownyearmolecularregulationof pages 1-11
53. raivolaUnknownyearmolecularregulationof pages 167-169
54. raivolaUnknownyearmolecularregulationof pages 23-27
55. raivolaUnknownyearmolecularregulationof pages 27-29
56. raivolaUnknownyearmolecularregulationof pages 30-33

Additionally, for substrate specificity of tyrosine kinases, see Yaron-Barir, T. M., Joughin, B. A., Huntsman, E. M., Kerelsky, A., Cizin, D. M., Cohen, B. M., … & Johnson, J. L. (2024). The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629(8014), 1174-1181; and for kinase phylogeny, see Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298(5600), 1912-1934, along with Manning, G., Plowman, G. D., Hunter, T., & Sudarsanam, S. (2002). Evolution of protein kinase signaling from yeast to man. Trends in biochemical sciences, 27(10), 514-520.

References

1. (babon2014themolecularregulation pages 1-3): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
2. (babon2014themolecularregulation pages 11-13): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
3. (babon2014themolecularregulation pages 14-15): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
4. (babon2014themolecularregulation pages 26-28): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
5. (babon2014themolecularregulation pages 4-6): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
6. (babon2014themolecularregulation pages 6-7): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
7. (babon2014themolecularregulation pages 9-11): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
8. (braidotti2023terapiadiprecisione pages 13-15): S Braidotti. Terapia di precisione per malattie autoimmuni mediate da chinasi: sviluppo di un sistema in vitro per la diagnosi e il monitoraggio clinico. Unknown journal, 2023.
9. (braidotti2023terapiadiprecisione pages 6-9): S Braidotti. Terapia di precisione per malattie autoimmuni mediate da chinasi: sviluppo di un sistema in vitro per la diagnosi e il monitoraggio clinico. Unknown journal, 2023.
10. (braidotti2023terapiadiprecisione pages 81-83): S Braidotti. Terapia di precisione per malattie autoimmuni mediate da chinasi: sviluppo di un sistema in vitro per la diagnosi e il monitoraggio clinico. Unknown journal, 2023.
11. (castelosoccio2023proteinkinasesdrug pages 5-7): Leslie Castelo-Soccio, Hanna Kim, Massimo Gadina, Pamela L. Schwartzberg, Arian Laurence, and John J. O’Shea. Protein kinases: drug targets for immunological disorders. Nature Reviews Immunology, 23:787-806, May 2023. URL: https://doi.org/10.1038/s41577-023-00877-7, doi:10.1038/s41577-023-00877-7. This article has 74 citations and is from a highest quality peer-reviewed journal.
12. (castelosoccio2023proteinkinasesdrug pages 7-8): Leslie Castelo-Soccio, Hanna Kim, Massimo Gadina, Pamela L. Schwartzberg, Arian Laurence, and John J. O’Shea. Protein kinases: drug targets for immunological disorders. Nature Reviews Immunology, 23:787-806, May 2023. URL: https://doi.org/10.1038/s41577-023-00877-7, doi:10.1038/s41577-023-00877-7. This article has 74 citations and is from a highest quality peer-reviewed journal.
13. (foulkes2018biochemicalanalysisof pages 59-63): DM Foulkes. Biochemical analysis of tribbles 2 pseudokinase using repurposed kinase inhibitors. Unknown journal, 2018.
14. (kwon2022moleculardissectionof pages 1-2): Sunghark Kwon. Molecular dissection of janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, Dec 2022. URL: https://doi.org/10.3389/fimmu.2022.1075192, doi:10.3389/fimmu.2022.1075192. This article has 13 citations and is from a peer-reviewed journal.
15. (kwon2022moleculardissectionof pages 2-4): Sunghark Kwon. Molecular dissection of janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, Dec 2022. URL: https://doi.org/10.3389/fimmu.2022.1075192, doi:10.3389/fimmu.2022.1075192. This article has 13 citations and is from a peer-reviewed journal.
16. (kwon2022moleculardissectionof pages 4-6): Sunghark Kwon. Molecular dissection of janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, Dec 2022. URL: https://doi.org/10.3389/fimmu.2022.1075192, doi:10.3389/fimmu.2022.1075192. This article has 13 citations and is from a peer-reviewed journal.
17. (kwon2022moleculardissectionof pages 6-8): Sunghark Kwon. Molecular dissection of janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, Dec 2022. URL: https://doi.org/10.3389/fimmu.2022.1075192, doi:10.3389/fimmu.2022.1075192. This article has 13 citations and is from a peer-reviewed journal.
18. (li2017insightsontype pages 14-20): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
19. (li2017insightsontype pages 20-22): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
20. (malemud2018theroleof pages 1-2): Charles J. Malemud. The role of the jak/stat signal pathway in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 10:117-127, May 2018. URL: https://doi.org/10.1177/1759720x18776224, doi:10.1177/1759720x18776224. This article has 305 citations and is from a peer-reviewed journal.
21. (raivolaUnknownyearmolecularregulationof pages 105-107): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
22. (raivolaUnknownyearmolecularregulationof pages 11-14): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
23. (raivolaUnknownyearmolecularregulationof pages 14-19): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
24. (raivolaUnknownyearmolecularregulationof pages 143-152): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
25. (raivolaUnknownyearmolecularregulationof pages 152-154): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
26. (raivolaUnknownyearmolecularregulationof pages 154-156): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
27. (raivolaUnknownyearmolecularregulationof pages 161-163): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
28. (raivolaUnknownyearmolecularregulationof pages 37-40): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
29. (raivolaUnknownyearmolecularregulationof pages 44-48): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
30. (raivolaUnknownyearmolecularregulationof pages 48-50): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
31. (raivolaUnknownyearmolecularregulationof pages 87-90): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
32. (zarrin2021kinaseinhibitionin pages 5-6): Ali A. Zarrin, Katherine Bao, Patrick Lupardus, and Domagoj Vucic. Kinase inhibition in autoimmunity and inflammation. Nature Reviews Drug Discovery, 20:39-63, Oct 2021. URL: https://doi.org/10.1038/s41573-020-0082-8, doi:10.1038/s41573-020-0082-8. This article has 384 citations and is from a highest quality peer-reviewed journal.
33. (babon2014themolecularregulation pages 3-4): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
34. (babon2014themolecularregulation pages 7-9): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
35. (klebl…2011proteinkinasesas pages 143-145): B. Klebl, G. Müller, and M. Hamacher. Protein kinases as drug targets. Methods and Principles in Medicinal Chemistry, Feb 2011. URL: https://doi.org/10.1002/9783527633470, doi:10.1002/9783527633470. This article has 39 citations.
36. (li2017insightsontype pages 156-158): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
37. (li2017insightsontype pages 22-26): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
38. (li2017insightsontype pages 26-30): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
39. (niranjan2014functionalcharacterizationof pages 10-14): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
40. (niranjan2014functionalcharacterizationof pages 110-111): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
41. (niranjan2014functionalcharacterizationof pages 14-19): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
42. (niranjan2014functionalcharacterizationof pages 38-41): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
43. (niranjan2014functionalcharacterizationof pages 41-46): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
44. (niranjan2014functionalcharacterizationof pages 96-99): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
45. (raivolaUnknownyearmolecularregulationof pages 1-11): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
46. (raivolaUnknownyearmolecularregulationof pages 167-169): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
47. (raivolaUnknownyearmolecularregulationof pages 23-27): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
48. (raivolaUnknownyearmolecularregulationof pages 27-29): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.
49. (raivolaUnknownyearmolecularregulationof pages 30-33): J RAIVOLA. Molecular regulation of janus kinases (jaks). Unknown journal, Unknown year.